Blaine Robinson has been appointed as a Vice President of Therapy Acceleration Program at The Leukemia and Lymphoma Society

Blaine Robinson has announced that he has started a new position as Vice President of the Therapy Acceleration Program at the Leukemia and Lymphoma Society

Blaine Robinson is an accomplished leader and expert in the fields of cancer research, drug development, and venture philanthropy, with over 14 years of experience at the Leukemia and Lymphoma Society (LLS), a leading organization dedicated to advancing treatments for blood cancers. His career has been marked by a strong focus on driving the success of innovative therapeutic initiatives, managing complex research programs, and spearheading initiatives that foster collaboration between the nonprofit sector and the biotech industry.

He provides strategic leadership and oversight to the highly successful venture philanthropy initiative. In this capacity, he works to bridge the gap between scientific discovery and commercialization, accelerating the development of novel therapies for blood cancers. His role involves cultivating partnerships with biotech and pharmaceutical companies, securing funding, and guiding the translation of groundbreaking research into clinical applications that have the potential to save lives.

Prior to his current role, Blaine served as the Executive Director of TAP from April 2019 to December 2024.

In this position, he led the strategic direction of the program, overseeing the identification, evaluation, and support of early-stage therapeutic projects. His work has been instrumental in the advancement of numerous promising cancer therapies, with a focus on those that can address the unmet needs of patients battling leukemia, lymphoma, and other blood cancers.

Before transitioning to TAP leadership, Blaine served as Senior Director of the program from 2015 to 2019.

During this period, he played a key role in the expansion of LLS’s venture philanthropy efforts, successfully managing a portfolio of therapeutic projects and establishing a strong track record of funding and collaboration with academic, nonprofit, and industry partners.

Blaine’s expertise in the pharmaceutical and biotech industries is grounded in his early career as a Research Associate at The Children’s Hospital of Philadelphia, where he contributed to advancements in pediatric oncology research from 2003 to 2010. His experience in the lab, combined with his leadership in venture philanthropy, gives him a unique perspective on both the scientific and business aspects of drug development.

Blaine holds a Ph.D. in Pharmacology from the University of Michigan, where he honed his scientific expertise and gained deep knowledge in drug discovery and development. He also earned a combined B.S./M.S. in Chemistry from Bucknell University, which provided the foundation for his strong analytical skills and scientific acumen.

Throughout his career, Blaine has been deeply committed to improving the lives of patients through the advancement of cancer therapies. His work continues to shape the landscape of blood cancer research, making a significant impact on the development of life-saving treatments and improving outcomes for patients worldwide.

Blaine Robinson shared a post on LinkedIn about his new position:

“I’m happy to share that I’m starting a new position as Vice President, Therapy Acceleration Program (TAP) at The Leukemia and Lymphoma Society! I wanted to thank the previous VPs (Keting Chu, Kenneth LaMontagne, PhD, MBA, Lore Gruenbaum) who helped guide me and TAP to where it is today! I’m looking forward to driving TAP into 2025 and beyond!”